Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01761877 · ClinicalTrials.gov registry record · Phase 2
NSAID Effects on Clinical and Imaging Breast Biomarkers
A Phase 2 study, sponsored by Stony Brook University.
- Completed
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
NCT01761877 is a Phase 2 study that has completed, run by Stony Brook University. The registered enrollment target is 114 participants.
The verdict
NCT01761877, a Phase 2 study, has completed, sponsored by Stony Brook University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
Study Summary
This study has two purposes. One is to determine if daily sulindac decreases breast density; a risk factor for breast cancer development. The second is to determine whether sulindac reduces pain and stiffness associated with regular use of aromatase inhibitors given for the treatment of breast cancer.
Interventions
- DRUG Sulindac
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2012-12 |
| Est. Completion | 2019-03-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01761877
The ClinicalTrials.gov registry entry for NCT01761877 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stony Brook University, which has 127 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sulindac is the first listed.
NCT01761877 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01761877 about?
NCT01761877 is a clinical study titled "NSAID Effects on Clinical and Imaging Breast Biomarkers". This study has two purposes. One is to determine if daily sulindac decreases breast density; a risk factor for breast cancer development. The second is to determine whether sulindac reduces pain and stiffness associated with regular use of aromatase inhibitors given for the treatment of breast cance...
What is the current status of trial NCT01761877?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2012-12. Estimated completion is 2019-03-11.
What interventions are being tested in trial NCT01761877?
The interventions under investigation include: Sulindac (DRUG).
Who is sponsoring clinical trial NCT01761877?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.